Strategic Collaborations Bactobio’s focus on novel antibiotics and sustainable plant protection via unculturable microbes makes them an attractive partner for pharma, biotech and agrochemical companies seeking early discovery collaborations or licensing of antimicrobial leads. Target business development outreach to propose joint discovery programs, co-development deals, and access to their unique microbial resources and genomics-driven screening capabilities.

Genomics and AI They combine genomics, machine learning and bioengineering to unlock microbial chemistries, creating demand for advanced data analytics, bioinformatics services and AI-driven genome mining. Opportunities exist to offer end-to-end analytics pipelines, cloud-based compute on their preferred platform, managed sequencing data processing, and collaboration on ML model development for lead optimization.

Grants and Programs With a history of public funding and financing rounds, Bactobio is well positioned for grant-funded R&D partnerships. Sales opportunities include offering grant management and co-funding services, assisting with proposal development, and delivering preclinical discovery work aligned with public programs such as Biomedical Catalyst-style initiatives.

Scale-up Partnerships As a mid-sized growth company, they may need CRO and bioprocess scale-up support to move leads toward preclinical stages. Potential sales opportunities include offering contract R&D, fermentation development, scale-up, and access to specialized lab automation or equipment suppliers that enable microbial culture at larger scales.

EU Market Access London-based Bactobio could leverage EU collaborations for antimicrobial and plant-protection solutions. Opportunities include distribution partnerships, regulatory consulting, and market-entry support in Europe, enabling faster access to customers in pharma, biotech and agriculture sectors.